Sacituzumab govitecan and pembrolizumab can produce a high response rate in previously treated, advanced urothelial carcinoma, according to researchers. Sacituzumab govitecan and pembrolizumab can produce a high response rate in previously treated, advanced urothelial carcinoma, according to researchers.
/PRNewswire/ The "Europe MRD Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com s offering. The Europe MRD.
Sacituzumab govitecan and pembrolizumab can produce a high response rate in previously treated, advanced urothelial carcinoma, according to researchers. Sacituzumab govitecan and pembrolizumab can produce a high response rate in previously treated, advanced urothelial carcinoma, according to researchers.
SALT LAKE CITY, Feb. 01, 2024 Myriad Genetics, Inc., , a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select.